Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols.

Engy Elekhnawy, Walaa A Negm, Suzy A El-Sherbeni, Ahmed Zayed
Author Information
  1. Engy Elekhnawy: Pharmaceutical Microbiology Department, Faculty of Pharmacy, Tanta University, Elguish Street (Medical Campus), Tanta, 31527, Egypt.
  2. Walaa A Negm: Pharmacognosy Department, Faculty of Pharmacy, Tanta University, Elguish Street (Medical Campus), Tanta, 31527, Egypt. walaa.negm@pharm.tanta.edu.eg. ORCID
  3. Suzy A El-Sherbeni: Pharmacognosy Department, Faculty of Pharmacy, Tanta University, Elguish Street (Medical Campus), Tanta, 31527, Egypt.
  4. Ahmed Zayed: Pharmacognosy Department, Faculty of Pharmacy, Tanta University, Elguish Street (Medical Campus), Tanta, 31527, Egypt.

Abstract

The pandemic spread of coronavirus (COVID-19) has been reported first at the end of 2019. It continues disturbing various human aspects with multiple pandemic waves showing more fatal novel variants. Now Egypt faces the sixth wave of the pandemic with controlled governmental measures. COVID-19 is an infectious respiratory disease-causing mild to moderate illness that can be progressed into life-threatening complications based on patients- and variant type-related factors. The symptoms vary from dry cough, fever to difficulty in breathing that required urgent hospitalization. Most countries have authorized their national protocols for managing manifested symptoms and thus lowering the rate of patients' hospitalization and boosting the healthcare systems. These protocols are still in use even with the development and approval of several vaccines. These protocols were instructed to aid home isolation, bed rest, dietary supplements, and additionally the administration of antipyretic, steroids, and antiviral drugs. The current review aimed to highlight the administered protocols in the Middle East, namely in Egypt and the Kingdom of Saudi Arabia demonstrating how these protocols have shown potential effectiveness in treating patients and saving many soles.

Keywords

References

  1. J Infect Public Health. 2020 Jun;13(6):834-838 [PMID: 32451260]
  2. Nat Rev Drug Discov. 2017 Dec;16(12):843-862 [PMID: 29104284]
  3. Int J Dev Biol. 2015;59(7-9):281-8 [PMID: 26679946]
  4. Front Public Health. 2020 May 19;8:209 [PMID: 32574298]
  5. Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):14408-14413 [PMID: 27911847]
  6. J Infect. 2021 Jan;82(1):e22-e24 [PMID: 32888976]
  7. Thromb Res. 2017 Jul;155:1-5 [PMID: 28460259]
  8. J Clin Invest. 2020 May 1;130(5):2620-2629 [PMID: 32217835]
  9. J Microbiol Immunol Infect. 2021 Aug;54(4):541-546 [PMID: 34435559]
  10. Am J Respir Crit Care Med. 2010 Oct 1;182(7):897-904 [PMID: 20224070]
  11. Infect Dis Rep. 2021 Apr 01;13(2):259-284 [PMID: 33915690]
  12. Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3390-3396 [PMID: 32271456]
  13. Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868 [PMID: 31806372]
  14. Nat Commun. 2020 Sep 17;11(1):4682 [PMID: 32943628]
  15. Curr Probl Cardiol. 2020 Aug;45(8):100618 [PMID: 32439197]
  16. JAMA. 2020 Sep 15;324(11):1048-1057 [PMID: 32821939]
  17. Bioorg Chem. 2020 Nov;104:104257 [PMID: 32927129]
  18. JAMA. 2020 Sep 8;324(10):951-960 [PMID: 32789505]
  19. N Engl J Med. 2020 May 7;382(19):1787-1799 [PMID: 32187464]
  20. J Infect Dis. 2021 Aug 2;224(3):415-419 [PMID: 33961695]
  21. Viruses. 2020 Dec 23;13(1): [PMID: 33374514]
  22. Immune Netw. 2013 Apr;13(2):70-4 [PMID: 23700397]
  23. Nat Struct Mol Biol. 2021 Sep;28(9):740-746 [PMID: 34381216]
  24. JAMA. 2020 Jun 23;323(24):2458-2459 [PMID: 32421155]
  25. N Engl J Med. 2020 Feb 20;382(8):727-733 [PMID: 31978945]
  26. J Allergy Clin Immunol. 2021 Jan;147(1):107-111 [PMID: 32920092]
  27. JAMA. 2020 Mar 17;323(11):1061-1069 [PMID: 32031570]
  28. Clin Infect Dis. 2023 Jan 6;76(1):165-171 [PMID: 35245942]
  29. J Med Virol. 2019 Jun;91(6):911-917 [PMID: 30729547]
  30. J Neuroimmune Pharmacol. 2020 Jun;15(2):174-180 [PMID: 32415419]
  31. Expert Rev Anti Infect Ther. 2021 Feb;19(2):147-163 [PMID: 32853038]
  32. N Engl J Med. 2020 Nov 12;383(20):1920-1931 [PMID: 32663912]
  33. N Engl J Med. 2022 Apr 14;386(15):1475-1477 [PMID: 35263535]
  34. N Engl J Med. 2020 Apr 30;382(18):1708-1720 [PMID: 32109013]
  35. Therapie. 2020 Jul - Aug;75(4):355-362 [PMID: 32418728]
  36. PLoS One. 2020 May 11;15(5):e0233147 [PMID: 32392262]
  37. EXCLI J. 2021 Feb 15;20:339-365 [PMID: 33746666]
  38. Transfus Apher Sci. 2020 Feb;59(1):102717 [PMID: 31902683]
  39. JAMA. 2020 Oct 6;324(13):1284-1285 [PMID: 32870268]
  40. Gut. 1992 May;33(5):617-21 [PMID: 1319381]
  41. Iran Red Crescent Med J. 2014 Aug;16(8):e12559 [PMID: 25389472]
  42. Lancet. 2020 Mar 28;395(10229):1054-1062 [PMID: 32171076]
  43. J Glob Antimicrob Resist. 2020 Dec;23:256-262 [PMID: 33065330]
  44. J Infect. 2020 Dec;81(6):952-960 [PMID: 32987097]
  45. Engineering (Beijing). 2020 Oct;6(10):1192-1198 [PMID: 32346491]
  46. Antibiotics (Basel). 2020 Apr 20;9(4): [PMID: 32326058]
  47. Nat Rev Microbiol. 2021 Mar;19(3):155-170 [PMID: 33116300]
  48. Med J Armed Forces India. 2020 Oct;76(4):370-376 [PMID: 32895599]
  49. Antiviral Res. 2019 Sep;169:104541 [PMID: 31233808]
  50. Int J Epidemiol. 2020 Jun 1;49(3):717-726 [PMID: 32086938]
  51. N Engl J Med. 2022 Feb 10;386(6):509-520 [PMID: 34914868]
  52. JAC Antimicrob Resist. 2020 Sep;2(3):dlaa071 [PMID: 32864608]
  53. medRxiv. 2021 Dec 30;: [PMID: 35018382]
  54. Lancet. 2020 Feb 15;395(10223):e30-e31 [PMID: 32032529]
  55. mBio. 2020 May 22;11(3): [PMID: 32444382]
  56. Therapie. 2020 Sep - Oct;75(5):514-515 [PMID: 32839015]
  57. Trends Pharmacol Sci. 2009 Oct;30(10):528-35 [PMID: 19762093]
  58. Lancet. 2020 May 16;395(10236):1569-1578 [PMID: 32423584]
  59. Adv Wound Care (New Rochelle). 2017 Jun 1;6(6):210-224 [PMID: 28616361]
  60. J Thromb Thrombolysis. 2020 Nov;50(4):814-821 [PMID: 32748122]
  61. J Allergy Clin Immunol. 2015 May;135(5):1171-8.e1 [PMID: 25458910]
  62. Clin Med (Lond). 2020 Mar;20(2):124-127 [PMID: 32139372]
  63. Nat Rev Rheumatol. 2020 Mar;16(3):155-166 [PMID: 32034323]
  64. Theochem. 2004 Jul 26;681(1):137-141 [PMID: 32287547]
  65. Am J Physiol Renal Physiol. 2003 Jan;284(1):F11-21 [PMID: 12473535]
  66. J Infect. 2021 Apr;82(4):84-123 [PMID: 33152376]
  67. Expert Rev Respir Med. 2021 Feb;15(2):277-284 [PMID: 32945710]
  68. Arch Gynecol Obstet. 2018 Sep;298(3):631-638 [PMID: 30039470]
  69. Lancet. 2014 Jun 14;383(9934):2073-2082 [PMID: 24857703]
  70. Maturitas. 2017 Feb;96:58-71 [PMID: 28041597]
  71. Crit Care. 2020 Apr 30;24(1):188 [PMID: 32354360]
  72. N Engl J Med. 2022 Jan 27;386(4):305-315 [PMID: 34937145]
  73. N Engl J Med. 2011 Mar 3;364(9):797-805 [PMID: 21366472]
  74. Transp Policy (Oxf). 2021 Sep;110:225-237 [PMID: 34608362]
  75. JAMA. 2020 Apr 14;323(14):1406-1407 [PMID: 32083643]
  76. Vaccines (Basel). 2020 Dec 06;8(4): [PMID: 33291245]
  77. Nat Rev Drug Discov. 2020 May;19(5):305-306 [PMID: 32273591]
  78. Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102 [PMID: 32258207]
  79. N Engl J Med. 2020 Oct 29;383(18):1757-1766 [PMID: 32329974]
  80. Sci Rep. 2020 Dec 17;10(1):22139 [PMID: 33335141]
  81. Trends Pharmacol Sci. 2020 Jun;41(6):363-382 [PMID: 32291112]
  82. Nutrients. 2017 Nov 03;9(11): [PMID: 29099763]
  83. Clin Pharmacokinet. 2016 Aug;55(8):907-23 [PMID: 26798032]
  84. J Infect. 2020 Aug;81(2):318-356 [PMID: 32283154]
  85. Antimicrob Agents Chemother. 2019 Sep 16;63(12): [PMID: 31527024]
  86. PLoS One. 2020 Sep 17;15(9):e0238678 [PMID: 32941467]
  87. Int J Antimicrob Agents. 2019 Apr;53(4):362-369 [PMID: 30599241]
  88. Diabetes Metab Syndr. 2022 Feb;16(2):102396 [PMID: 35051686]
  89. Theranostics. 2021 Jan 1;11(3):1207-1231 [PMID: 33391531]
  90. Int J Environ Res Public Health. 2020 Sep 14;17(18): [PMID: 32937929]
  91. Lancet Infect Dis. 2020 Aug;20(8):896-897 [PMID: 32353346]
  92. East Mediterr Health J. 2016 Apr 28;22(2):85-6 [PMID: 27180735]
  93. J Thromb Thrombolysis. 2016 Jan;41(1):15-31 [PMID: 26780737]
  94. Lancet. 2020 Nov 7;396(10261):1525-1534 [PMID: 32979936]
  95. BMC Public Health. 2020 Dec 3;20(1):1853 [PMID: 33272250]
  96. N Engl J Med. 2021 Mar 4;384(9):795-807 [PMID: 33306283]
  97. JAMA. 2020 Sep 8;324(10):931-932 [PMID: 32766736]
  98. Transbound Emerg Dis. 2021 Mar;68(2):213-215 [PMID: 32892500]
  99. Future Microbiol. 2020 Jul;15:959-962 [PMID: 32662664]
  100. Lancet Infect Dis. 2020 May;20(5):533-534 [PMID: 32087114]
  101. Vaccines (Basel). 2021 Apr 18;9(4): [PMID: 33919586]
  102. Ann Intensive Care. 2020 Jun 6;10(1):73 [PMID: 32506258]
  103. Lancet Infect Dis. 2020 Apr;20(4):400-402 [PMID: 32113509]
  104. Anaesthesia. 2020 Jul;75(7):843-847 [PMID: 32246843]
  105. Antiviral Res. 2013 Nov;100(2):446-54 [PMID: 24084488]
  106. JAMA. 2020 Jun 23;323(24):2460-2461 [PMID: 32453392]
  107. Int Immunol. 2017 Dec 30;29(11):491-498 [PMID: 28666326]
  108. Eur J Pharmacol. 2020 Nov 5;886:173546 [PMID: 32931782]
  109. J Med Virol. 2020 Jun;92(6):556-563 [PMID: 32104907]
  110. Postgrad Med J. 2021 Mar;97(1145):175-179 [PMID: 32732260]
  111. Microb Pathog. 2020 Aug;145:104228 [PMID: 32344177]
  112. Science. 2021 Dec 24;374(6575):1586-1593 [PMID: 34726479]
  113. Am J Kidney Dis. 2019 Nov;74(5):682-695 [PMID: 31227226]
  114. BMJ. 2020 Apr 2;369:m1375 [PMID: 32241884]
  115. Lancet Public Health. 2020 Jun;5(6):e310 [PMID: 32339478]
  116. Front Pharmacol. 2020 Sep 16;11:579886 [PMID: 33041824]
  117. Medicine (Baltimore). 2018 Aug;97(31):e11384 [PMID: 30075504]
  118. Res Pract Thromb Haemost. 2019 Nov 26;4(1):36-45 [PMID: 31989083]
  119. Nat Commun. 2020 Jan 10;11(1):222 [PMID: 31924756]
  120. Clin Immunol. 2020 Jun;215:108427 [PMID: 32325252]
  121. Lancet Public Health. 2020 Nov;5(11):e575 [PMID: 32971009]
  122. J Postgrad Med. 2009 Jul-Sep;55(3):225-30 [PMID: 19884755]
  123. Expert Rev Anti Infect Ther. 2010 May;8(5):505-14 [PMID: 20455679]
  124. Ann Intern Med. 2014 Mar 18;160(6):389-97 [PMID: 24474051]
  125. Pediatr Pulmonol. 2018 May;53(5):567-574 [PMID: 29405608]
  126. Rev Panam Salud Publica. 2020 Mar 20;44:e40 [PMID: 32256547]
  127. BMC Infect Dis. 2020 Oct 21;20(1):786 [PMID: 33087047]
  128. Lancet. 2020 Feb 15;395(10223):497-506 [PMID: 31986264]
  129. Autoimmun Rev. 2020 Jun;19(6):102537 [PMID: 32251717]
  130. Eur Respir J. 1995 Apr;8(4):637-42 [PMID: 7664866]
  131. Sci Transl Med. 2022 Jan 19;14(628):eabl7430 [PMID: 34941423]
  132. Int J Antimicrob Agents. 2020 May;55(5):105951 [PMID: 32234466]
  133. N Engl J Med. 2022 Apr 14;386(15):1397-1408 [PMID: 35172054]
  134. N Engl J Med. 2020 Jun 18;382(25):2411-2418 [PMID: 32379955]
  135. Arch Med Res. 2020 Aug;51(6):585-586 [PMID: 32439198]
  136. Pharmacotherapy. 2021 Nov;41(11):884-906 [PMID: 34558742]
  137. China CDC Wkly. 2020 Feb 21;2(8):113-122 [PMID: 34594836]
  138. Med Hypotheses. 2020 Oct;143:110018 [PMID: 32679422]
  139. Clin Infect Dis. 2020 Dec 3;71(9):2459-2468 [PMID: 32358954]
  140. J Biomol Struct Dyn. 2021 Apr;39(7):2673-2678 [PMID: 32248766]
  141. Lancet. 2020 Feb 15;395(10223):473-475 [PMID: 32043983]
  142. J Med Internet Res. 2021 Jan 15;23(1):e25830 [PMID: 33302252]
  143. Eur Respir J. 2020 Jul 16;56(1): [PMID: 32430428]
  144. Clin Microbiol Infect. 2020 Oct;26(10):1395-1399 [PMID: 32603803]
  145. J Matern Fetal Neonatal Med. 2021 Mar;34(6):966-978 [PMID: 31092073]
  146. J Antibiot (Tokyo). 2019 Oct;72(10):759-768 [PMID: 31300721]
  147. Expert Opin Pharmacother. 2018 Sep;19(13):1441-1450 [PMID: 30185087]
  148. Int J Biol Sci. 2020 Mar 15;16(10):1678-1685 [PMID: 32226285]
  149. J Clin Pharm Ther. 2021 Jun;46(3):610-621 [PMID: 33533509]
  150. East Mediterr Health J. 2013;19 Suppl 1:S19-25 [PMID: 23888791]
  151. SN Compr Clin Med. 2020;2(12):2600-2620 [PMID: 33103063]
  152. Pediatr Res. 2020 Feb;87(3):463-471 [PMID: 31493768]
  153. Adv Physiol Educ. 2016 Dec;40(4):480-490 [PMID: 27756725]
  154. Antivir Ther. 2012;17(3):467-76 [PMID: 22293206]
  155. JAMA Intern Med. 2020 Jul 1;180(7):934-943 [PMID: 32167524]
  156. JAMA. 1999 Oct 6;282(13):1240-6 [PMID: 10517426]
  157. Nature. 2020 Sep;585(7826):588-590 [PMID: 32698190]
  158. J Antimicrob Chemother. 2005 Feb;55 Suppl 1:i5-i21 [PMID: 15709056]
  159. Biomed Pharmacother. 2020 Nov;131:110668 [PMID: 32861965]
  160. J Infect Chemother. 2009 Dec;15(6):374-9 [PMID: 20012727]
  161. Prog Cardiovasc Dis. 2020 May - Jun;63(3):383-385 [PMID: 32061635]
  162. Int J Environ Res Public Health. 2020 Aug 11;17(16): [PMID: 32796733]
  163. Arch Med Res. 2020 Oct;51(7):741-742 [PMID: 32546446]
  164. Lancet. 2020 Feb 15;395(10223):507-513 [PMID: 32007143]
  165. Biochem Biophys Res Commun. 2019 Jul 12;515(1):31-36 [PMID: 31122698]
  166. Neuroimmunomodulation. 2015;22(1-2):20-32 [PMID: 25227506]
  167. J Med Chem. 2016 Jul 28;59(14):6595-628 [PMID: 26878082]
  168. Case Rep Crit Care. 2016;2016:8560871 [PMID: 27891260]
  169. Expert Rev Clin Pharmacol. 2021 Oct;14(10):1279-1287 [PMID: 34187281]
  170. J Genet Genomics. 2020 Feb 20;47(2):119-121 [PMID: 32173287]
  171. PLoS Negl Trop Dis. 2018 Oct 24;12(10):e0006848 [PMID: 30356305]
  172. J Clin Med. 2020 Mar 31;9(4): [PMID: 32244365]
  173. Medchemcomm. 2019 Jun 28;10(10):1719-1739 [PMID: 31803393]
  174. Int J Antimicrob Agents. 2020 Jul;56(1):105949 [PMID: 32205204]
  175. J Biomed Sci. 2021 Jan 12;28(1):9 [PMID: 33435929]
  176. Rheum Dis Clin North Am. 2016 Feb;42(1):15-31, vii [PMID: 26611548]
  177. J Rheumatol. 2017 Mar;44(3):398 [PMID: 28250164]
  178. Phytomedicine. 2021 May;85:153311 [PMID: 33067112]
  179. Trials. 2020 Feb 26;21(1):225 [PMID: 32102680]
  180. Clin Drug Investig. 2020 Aug;40(8):683-686 [PMID: 32533455]
  181. Pediatr Surg Int. 2005 Oct;21(10):800-5 [PMID: 16205929]

MeSH Term

Humans
Pharmaceutical Preparations
Pandemics
Antiviral Agents
Middle East
COVID-19 Drug Treatment

Chemicals

Pharmaceutical Preparations
Antiviral Agents

Word Cloud

Created with Highcharts 10.0.0protocolspandemicCOVID-19EgyptMiddleEastsymptomshospitalizationdrugsadministeredSaudiArabiaspreadcoronavirusreportedfirstend2019continuesdisturbingvarioushumanaspectsmultiplewavesshowingfatalnovelvariantsNowfacessixthwavecontrolledgovernmentalmeasuresinfectiousrespiratorydisease-causingmildmoderateillnesscanprogressedlife-threateningcomplicationsbasedpatients-varianttype-relatedfactorsvarydrycoughfeverdifficultybreathingrequiredurgentcountriesauthorizednationalmanagingmanifestedthusloweringratepatients'boostinghealthcaresystemsstilluseevendevelopmentapprovalseveralvaccinesinstructedaidhomeisolationbedrestdietarysupplementsadditionallyadministrationantipyreticsteroidsantiviralcurrentreviewaimedhighlightnamelyKingdomdemonstratingshownpotentialeffectivenesstreatingpatientssavingmanysolesAssessmentpartmanagementAntiviralProtocol

Similar Articles

Cited By